PacBio Announces Revio, a Revolutionary New Long Read Sequencing System Designed to Provide 15 Times More HiFi Data and Human Genomes at Scale for Under $1,000
/PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Revio™ long-read...
Source: prnewswire.com